State Street SPDR S&P Biotech ETF
146 hedge funds and large institutions have $2.16B invested in State Street SPDR S&P Biotech ETF in 2014 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 11 closing their positions.
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 11
46.15% more ownership
Funds ownership: 417.23% → 463.38% (+46%)
28% more capital invested
Capital invested by funds: $1.68B → $2.16B (+$479M)
17% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 42
13% more funds holding
Funds holding: 129 → 146 (+17)
52% less call options, than puts
Call options by funds: $65.8M | Put options by funds: $137M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$160M |
| 2 |
Citigroup
New York
|
+$16.4M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$5.55M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$39.5M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$16.8M |
| 3 |
JP Morgan Chase
New York
|
-$16.7M |
| 4 |
Goldman Sachs
New York
|
-$14.9M |
| 5 |
SG Americas Securities
New York
|
-$4.37M |
XBI Hedge Fund Activity: Q4 2014 in Review
146 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2014, worth a combined $2.16B — up 28% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new XBI positions and 11 closed out — a net gain of 22 holders — while 49 added to existing stakes and 42 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $160M. The largest seller was Morgan Stanley, cutting an estimated $39.5M.
- 146 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2014, up from 129 in Q3 2014.
- Funds reported $2.16B of State Street SPDR S&P Biotech ETF stock for Q4 2014, up 28% quarter-over-quarter.
- 33 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2014 and 11 closed out, a net change of +22 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2014 was Deutsche Bank, an estimated $160M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2014 was Morgan Stanley, an estimated $39.5M sold.
Based on aggregated 13F filings for Q4 2014.